About CancerPath
We help international patients access GC101 TIL cell therapy clinical trials in China — with free eligibility screening and personalized guidance.
Our Mission
CancerPath was founded to bridge the information gap between Chinese clinical research in TIL cell therapy and international patients who may benefit from it. We believe that geographic boundaries should not prevent patients from accessing potentially life-saving treatments.
China is one of the most advanced countries in the world for cell therapy clinical trials. However, for English-speaking patients abroad, navigating the Chinese healthcare system, understanding clinical trial eligibility, and coordinating treatment logistics can be overwhelming. CancerPath exists to make this process accessible, transparent, and stress-free.
Free service: Our initial eligibility assessment is always free. We do not charge patients for reviewing medical records, answering questions, or providing guidance about TIL therapy options.
What We Do
- Free eligibility screening: Review your medical records and determine whether GC101 TIL therapy may be appropriate for your specific cancer type and stage.
- Clinical trial matching: Help you identify the right clinical trial and connect you with the principal investigator team.
- Logistical coordination: Guide you through the treatment journey — from initial consultation to follow-up monitoring.
- Ongoing support: Remain available throughout your treatment and recovery for questions and assistance.
Our Team
CancerPath works closely with the leading oncology investigators in China who lead GC101 and GC203 clinical trials. Our network includes:
- Shun Lu (陆舜) — Thoracic Oncology, Shanghai Chest Hospital. PI of MIZAR-005 GC101 trial in advanced NSCLC.
- Jun Guo (郭军) — Melanoma and Sarcoma Oncology, PKU Cancer Hospital. PI of MIZAR-003 GC101 trial in advanced melanoma. ASCO 2026 LBA presenter.
- Xiaohua Wu (吴小华) — Gynecologic Oncology, Fudan University Shanghai Cancer Center. PI of GC203 TIL trial for ovarian cancer.
Our Values
Patient First
Every recommendation we make is guided by what is best for the patient, not by commercial interests.
Transparency
We provide clear, complete information about treatment options, costs, risks, and expected outcomes.
Scientific Rigor
Our guidance is based on published clinical data and direct communication with principal investigators.
Cultural Bridge
We navigate language, cultural, and healthcare system differences so you can focus on treatment.
Contact Us
Ready to explore whether GC101 TIL therapy is right for you? Start with a free eligibility assessment by emailing us your medical records.
Email: clinicaltrials@juncell.com
Response time: We respond to all enquiries within 48 hours.
Languages: English, Chinese
Frequently Asked Questions About CancerPath
What is CancerPath?
CancerPath is an independent patient advisory service helping international patients access GC101 TIL cell therapy clinical trials in China. We provide free eligibility screening, clinical trial matching, and logistical guidance — at no cost to patients.
Does CancerPath charge patients?
No. CancerPath's advisory services are free for patients. We earn a referral coordination fee from Juncell Therapeutics, not from patients. All treatment costs are covered by the clinical trial sponsor.
Is CancerPath a medical tourism agency?
No. We do not arrange travel, visas, or accommodation. We help patients understand eligibility, prepare medical records, and connect with Juncell's clinical team at leading cancer hospitals in China.
How do I start the process?
Email clinicaltrials@juncell.com for a free eligibility assessment. Include the patient's diagnosis, treatment history, and current imaging reports. We respond to all enquiries within 48 hours.